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Abstract Hereditary leiomyomatosis and renal cell can-
cer (HLRCC) is an autosomal dominant syndrome char-
acterized by skin piloleiomyomas, uterine leiomyomas and
papillary type 2 renal cancer caused by germline mutations
in the fumarate hydratase (FH) gene. Previously, we pro-
posed renal imaging for FH mutation carriers starting at the
age of 20 years. However, recently an 18-year-old woman
from a Dutch family with HLRCC presented with meta-
static renal cancer. We describe the patient and family data,
evaluate current evidence on renal cancer risk and sur-
veillance in HLRCC and consider the advantages and
disadvantages of starting surveillance for renal cancer in
childhood. We also discuss the targeted therapies admin-
istered to our patient.
Keywords Hereditary leiomyomatosis  Papillary renal
cancer  Fumarate hydratase
Introduction
In Western Europe the lifetime risk for renal cancer is
about 1% for men and 0.5% for women. In The Nether-
lands, for the period 2008–2009, the mean age at diagnosis
of renal cancer was 64 years and 90% of cases were
diagnosed after the age of 50 years. Histologically, 74% of
these cancers were of the clear cell (or unspeciﬁed) sub-
type, whereas papillary renal cancer was diagnosed in 7%
of cases (O. Visser, Netherlands Comprehensive Cancer
Centre, personal communication 2011).
Hereditary renal cancer is the common denominator for
a heterogeneous group of conditions, which includes Von
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itary papillary renal cancer, hereditary leiomyomatosis and
renal cell cancer (HLRCC) and other syndromes. In gen-
eral, hereditary renal cancer presents at an early age and is
often multifocal and/or bilateral. Notably, each condition is
characterized by a predominant histological subtype of
cancer, for example, Von Hippel-Lindau disease is char-
acterized by multiple, early-onset, clear cell renal tumours
[1, 2].
In hereditary leiomyomatosis and renal cell cancer
(HLRCC, MIM 605839), also known as multiple uterine
and cutaneous leiomyomatosis (MUCL, MIM 150800),
patients develop multiple cutaneous piloleiomyomas and
women develop, in addition, multiple and often symp-
tomatic uterine leiomyomas. A small subset of cases
develops papillary type 2 renal cancer, which often runs an
unfavourable clinical course. Other histological types of
renal cancer may also occur, in particular collecting duct
cancer [3–5]. HLRCC is an autosomal dominant condition
caused by heterozygous mutations in the fumarate hydra-
tase (FH) gene [6]. In contrast with other forms of hered-
itary renal cancer, most renal tumours in HLRCC are
unifocal and unilateral. Although renal cancer has been
consistently reported in a subset of HLRCC families, the
percentages of families in which renal cancer was observed
has varied widely, from 2 [7] to 50% [5] of the kindreds
studied (see Table 1). The reasons for the different reported
prevalences have not been clariﬁed. Although the risk of
renal cancer may differ between populations, the reported
variation in prevalence may also be due to the method of
ascertainment, i.e. via the dermatologist or urologist. No
clear genotype-phenotype correlations have been found for
HLRCC: as yet no association has been found between the
renal cancer phenotype and the type or location of the FH
mutation or FH enzyme activity [8, 9]. Vahteristo et al.
[10] found no evidence for a genetic modiﬁer for renal
cancer risk.
Although early age at onset of renal cancer is common
in HLRCC, onset before the age of 20 years is relatively
rare. The youngest age at diagnosis was recently reported
by Alrashdi et al. [11]: an 11-year-old FH mutation carrier
in whom localized asymptomatic renal cancer was detected
by presymptomatic renal imaging. This patient is doing
well three years after nephrectomy (S. V. Hodgson, per-
sonal communication 2011). Among 89 cases reported in
the literature, six (7%) were found in individuals younger
than 20 years (see Fig. 1). The main characteristics of renal
cancer in the early-onset cases that have been reported are
summarized in Table 2. Most cases for which relevant data
were available presented with metastatic disease.
Previously, we described the clinical and genetic ﬁnd-
ings in HLRCC families in The Netherlands [12]. In this
cohort of 14 families with FH mutations, we indentiﬁed
one case of renal cancer papillary type 2 and one Wilms
tumour. The association of the latter tumour with HLRCC
is uncertain [13]. Based on the literature data and our own
ﬁndings, in 2010 we advocated intensive renal surveillance
from age 20 onward, using ultrasound every 6 months and
annual MRI.
Recently, an 18-year-old woman from a Dutch HLRCC
family presented with symptomatic metastatic renal cancer.
Table 1 Proportion of HLRCC families with one or more cases of
renal cancer
Total no. of families Total no. and percentage
of families with renal cancer
Reference
18 2 (11%) [32]
46 1 (2%) [7]
56 18 (32%) [8]
14 1 (7%) [12]
14 7 (50%) [5]
44 15 (34%) [23]
Fig. 1 Age distribution of renal
cancer in 89 published patients
with HLRCC [3, 7, 11, 12,
15–24]
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123Here we present the patient and family data, review the
renal cancer risk in HLRCC, and consider the advantages
and disadvantages of intensive surveillance starting in
childhood. We also discuss our choices for targeted treat-
ment of metastatic papillary type 2 renal cancer in this
case.
Patient and pedigree data
The pedigree of this family is depicted in Fig. 2. A novel
pathogenic germline missense FH mutation, c.1002T[G,
p.Ser334Arg in exon 7, was detected in this kindred and
previously reported by Badeloe et al. [14]. At the time of
the original report, the family member we present here
(Fig. 2, patient III-4) was 15 years old and apparently
unaffected (not clinically evaluated). We advised genetic
analysis around age 18. Three years later, the patient was
referred with symptoms of fatigue, weight loss and cough.
At physical examination enlarged cervical lymph nodes
and a large right abdominal mass were palpable. Several
small skin lesions on the back were indicative of leio-
myomas, but histological examination was not performed.
CT scans showed a tumour in the right kidney, extensive
cervical, mediastinal, abdominal and retroperitoneal lym-
phadenopathy, and bone metastases (Fig. 3). No uterine
abnormalities were noted. A biopsy taken from a cervical
lymph node showed a metastatic carcinoma with a papil-
lary architecture and cells with prominent nucleoli. The
histological pattern corresponded with type 2 papillary
carcinoma. Focally, there were atypical large nucleoli
surrounded by a halo, which according to Merino et al. [3]
is a typical ﬁnding for HRLCC-associated renal cancer
(Fig. 4). Immunohistochemistry showed positive staining
for CK pan, CK 8/18, vimentin and CD10. Staining was
negative for CK7, CK20, Ber-Ep4, calcitonin, thyroglob-
ulin, EMA, CD15, PR, ER, TTF-1, CEA, P63 and OC125.
These immuno-histochemical ﬁndings were also compati-
ble with primary renal cell carcinoma, papillary type 2. The
patient was shown to be a carrier of the familial FH
germline mutation.
Initial systemic treatment consisted of sunitinib, a multi-
tyrosine kinase inhibitor. After two 6-week cycles stable
disease was documented and therapy was continued.
However, 5 months after initiation of therapy, progressive
disease developed with pleural effusion, treated by drain-
age and pleurodesis. Second line systemic treatment with
temsirolimus, an inhibitor of mammalian target of rapa-
mycin (mTOR), was started, but after eight weekly
administrations CT scans revealed progressive disease.
Further treatment consisted of symptom control and the
patient died 8 months after the diagnosis.
Discussion
The patient described in this report is a member of a pre-
viously described kindred with HLRCC, in which only skin
and uterine leiomyomas had occurred thus far. The proto-
col for these families proposed by the Dutch national
working group on HLRCC advocates intensive screening
for renal cancer from the age of 20 years onward [12].
Table 2 Characteristics of renal cancer cases in HLRCC families diagnosed before the age of 20 years
Patient no. Age at diagnosis
(years)
Histology Stage at
diagnosis
Outcome Reference
1 11 Papillary type 2 Stage 1 No evidence of disease 3 years
after diagnosis
[11]; S. V. Hodgson, personal
communication 2011
2 16 Collecting duct Metastatic Died at age 18 years [7]
3 17 Papillary type 2 Metastatic Died 15 months after
diagnosis
[19]
4 17 Papillary type 2 Metastatic Died at age 19 years [23]; M.H. Tan, personal
communication 2011
51 7 [3]
61 8 [3]
7 18 Papillary type 2 Metastatic Died 8 months after diagnosis Our case
Fig. 2 Pedigree of our HLRCC family. Abbreviations: Sk = skin
piloleiomyomas, Ut = uterine leiomyomas
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123Other authors have also proposed surveillance starting in
the 18–20 year age range [5]. However, Alrashdi et al. [11]
advocated surveillance starting in childhood, based on
childhood-onset cases. The patient described here pre-
sented with symptomatic metastatic papillary type 2 renal
cancer at the age of 18 years. This led us to reconsider the
arguments in favour of genetic testing and surveillance for
FH mutation carriers starting in childhood.
One of the main unresolved issues is the renal cancer
risk for FH mutation carriers. The reported proportion of
FH mutation-positive families with renal cancer among all
the kindreds studied varies widely as summarized in
Table 1. We have previously observed only one HLRCC
family with one papillary renal cancer case among 14
known FH mutation-positive families [12]. The different
prevalence ﬁgures reported may reﬂect various forms of
bias, in particular in the ascertainment of the disease in
dermatology versus urology clinics, or they might indicate
different renal cancer risks for different populations. Thus
no reliable renal cancer risk for a FH mutation carrier has
yet been determined. The second relevant issue is the age
distribution of HLRCC-associated renal cancer. Whereas
onset at the age of 30–45 years is common, onset before
age 20 is relatively rare, as shown in Table 2 and Fig. 1.
Among 89 patients reported with HLRCC-associated renal
cancer [3, 7, 11, 12, 15–24], only six cases (7%) were
diagnosed before the age of 20 [3, 7, 11, 19, 23]. Finally,
the biological behaviour of renal cancer in HLRCC and its
implication on surveillance should be considered. HLRCC-
associated renal cancer often runs an aggressive clinical
course. Long-term follow-up data are available on the
initial 19 renal cancer patients with HLRCC diagnosed at
the National Institute of Health, USA. In two of these
patients the kidney tumours were detected by surveillance.
Thirteen patients had advanced disease at presentation
(stage III or IV), three of which had distant metastasis. At a
median follow-up of 34 months (range 6–141 months)
seven patients had died due to disease, three had disease
and nine were free of detectable disease at last follow-up.
Based on these observations, the authors concluded that
renal tumours in HLRCC are signiﬁcantly more aggressive
than in patients with other hereditary tumour syndromes
Fig. 3 CT imaging of the
abdomen in the 18-year old
patient showing: massive
cervical (a) mediastinal (b) and
abdominal
(c) lymphadenopathy; the large
renal cell carcinoma of the right
kidney (d and e; arrow); and a
bone metastasis in the iliac bone
on the left side (f)
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123[4]. For Von Hippel –Lindau disease it has been established
that surveillance for renal cancer and nephron-sparing
treatment for lesions of 3 cm or larger is an effective
procedure [25]. For HLRCC-associated tumours that may
grow and spread aggressively, early radical treatment by
nephrectomy has been proposed. However, in HLRCC it is
currently unknown to what extent intensive surveillance
leading to early detection and treatment of malignant
lesions will lead to a reduction in mortality.
Systemic therapy for metastatic renal cell cancer has
evolved rapidly over the last 5 years. Immunotherapy has
largely been replaced by molecularly targeted agents that
inhibit angiogenesis. These targeted agents were developed
after it was recognized that VHL (Von Hippel-Lindau)
mutations, present in most clear cell renal cancers, lead to
accumulation of HIF (hypoxia inducible factor) and the
activation of cellular mechanisms which, in normal con-
ditions, become active as a response to hypoxia. One of
these mechanisms is the induction of angiogenesis by
production of the pro-angiogenic growth factors VEGF
(vascular endothelial growth factor) and PDGF (platelet-
derived growth factor). Currently, there is no standard
systemic treatment for advanced non-clear cell renal can-
cer. However, there is evidence that biallelic loss of
fumarate hydratase in HLRCC tumors results in VHL-
independent HIF accumulation [26, 27]. Therefore, treat-
ment with sunitinib, which blocks downstream effects of
HIF activation, was chosen for this patient. For papillary
renal cell cancer the reported response rates for sunitinib
treatment ranged from 0 to 17% and progression-free sur-
vival from 1.6 to 11.9 months [28–30]. Unfortunately, in
most of these studies, no distinction was made between
type 1 and type 2 papillary renal cell cancer and speciﬁc
data for HLRCC were lacking. HIF pathway can also be
blocked by inhibiting its positive regulator mammalian
target of rapamycin (mTOR) with temsirolimus (admis-
tered intravenously). Exploratory subgroup analysis of a
3-arm phase III study comparing temsirolimus, interferon,
and temsirolimus plus interferon revealed that patients with
papillary renal cell cancer treated with temsirolimus had a
better progression-free survival and overall survival than
patients treated with interferon [31]. Unfortunately, also for
temsirolimus no speciﬁc data for HLRCC are available.
One HLRCC case with metastatic cancer unsuccessfully
treated with temsirolinus plus a glycolytic inhibitor
2-deoxy-D-glucose was reported [24]. The course of dis-
ease in our patient was aggressive and the effect of treat-
ment was disappointing. Prospective multicentre studies
are necessary to assess the optimal treatment for patients
with metastatic renal cancer associated with HLRCC. But
it seems unrealistic to reach enough HLRCC cases for such
a trail, unless a global network is established. Currently, a
phase II study for HLRCC and sporadic papillary renal cell
cancer (bevacizumab and erlotinib) (NCT01130519), and
single agent phase II studies with foretinib (NCT00726323),
sunitinib (NCT00541008) and everolimus (NCT00688753)
for papillary renal cell cancer are ongoing in the USA and
France.
In summary, the optimal management for HLRCC has
not yet been established. Renal cancer risk is increased in
this syndrome, and it has been suggested that perhaps renal
cancer surveillance could be restricted to families with
previous cases of renal cancer or speciﬁc FH mutations [7].
However, there is no evidence that family history or the
type of FH mutation can predict renal cancer risk. There-
fore, current data indicate that surveillance should be
aimed at all FH mutation carriers. Apparently, renal cancer
in this syndrome may occur between 10 and 20 years of
age, and its successful early detection and treatment in an
11-year-old FH mutation carrier has been reported [11]. In
general, presymptomatic genetic testing in children is
performed if disease and death due to the hereditary
Fig. 4 Histological image of a biopsy taken from a cervical lymph
node in the patient showing metastatic carcinoma with a papillary
architecture (a 1009) and in the nuclei prominent nucleoli (b 2009)
(hematoxylin and eosin)
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123condition can be prevented by an early start of preventive
measures. The optimal policy for HLRCC has not yet been
established. The early-onset cases reported previously and
the present case have led us to consider the option of
childhood genetic testing for HLRCC families with a
pathogenic FH mutation and renal surveillance in mutation
carriers. Since renal cancer risk is probably low in child-
hood some may want to restrict this procedure for families
with early-onset renal cancer cases. MRI is clearly the most
sensitive option and regular CT scanning is contra-indi-
cated because of radiation dose. Since MRI might be dis-
tressing in childhood, we propose renal ultrasound every
6 months performed by an expert radiologist when sur-
veillance is started at or around 10 years of age followed at
a later age (16–18 years) by alternating MRI and ultra-
sound every 6 months. Close monitoring of our cohort of
patients and collaboration of the centres studying HLRCC
will provide data needed for future protocols on surveil-
lance and treatment.
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